使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Thank you for standing by. My name is Tina, and I will be your conference operator today. At this time, I would like to welcome everyone to the Pulse Biosciences Q2 2026 earnings call. (Operator Instructions)
感謝您的耐心等候。我叫 Tina,今天將擔任本次電話會議的接線員。此刻,我謹代表公司歡迎各位參加 Pulse Biosciences 2026 年第二季財報電話會議。(接線員指示)
It is now my pleasure to turn the call over to Philip Taylor, Investor Relations. Please go ahead.
現在我很榮幸將電話交給投資人關係的 Philip Taylor。請開始。
Philip Taylor - Investor Relations
Philip Taylor - Investor Relations
Thank you, operator.
謝謝,接線員。
Before we begin, I'd like to inform you that comments and responses to your questions during today's call reflect management's views as of today, August 6, 2026, only, and will include forward-looking statements and opinion statements, including predictions, estimates, plans, expectations, and other similar information. Actual results may differ materially from those expressed or implied as a result of certain risks and uncertainties.
在開始之前,我想提醒各位,今天電話會議中管理層對各位提問的評論與回覆,僅反映截至今天(2026 年 8 月 6 日)的管理層觀點,並將包含前瞻性陳述與意見性陳述,包括預測、估計、計畫、預期以及其他類似資訊。由於某些風險與不確定性,實際結果可能與明示或暗示的內容存在重大差異。
These risks and uncertainties are more fully described in our press release issued today and in our filings with the US Securities and Exchange Commission. Our SEC filings can be found on our website or on the SEC's website. Investors are cautioned not to place undue reliance on forward-looking statements. We disclaim any obligation to update or revise these forward-looking statements.
這些風險與不確定性在我們今日發布的新聞稿以及向美國證券交易委員會(SEC)提交的文件中有更完整的說明。我們的 SEC 申報文件可在公司網站或 SEC 網站查閱。提醒投資人不要過度依賴前瞻性陳述。我們不承擔更新或修訂這些前瞻性陳述的任何義務。
We will also discuss certain non-GAAP financial measures, disclosures regarding these non-GAAP financial measures, including reconciliations with the most comparable GAAP measures, can be found in the press release. Please note that this conference call will be available for audio replay on our website at pulsebiosciences.com in the News and Events section on our Investor Relations page.
我們也將討論若干非 GAAP 財務衡量指標;關於這些非 GAAP 財務衡量指標的揭露(包括與最可比 GAAP 指標的調節表)可在新聞稿中查閱。請注意,本次電話會議將提供音訊重播,可至 pulsebiosciences.com 網站投資人關係頁面的「新聞與活動」區收聽。
With that, I would now like to turn the call over to Co-Chair of the Board and Chief Executive Officer, Paul LaViolette.
接下來,我想把電話交給董事會共同主席兼執行長 Paul LaViolette。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thank you, Trip. And good afternoon, and thank you everyone for joining us today to discuss the results of our very active second quarter of 2026.
謝謝你,Trip。各位下午好,也感謝大家今天加入我們,一同討論 2026 年第二季非常活躍的營運成果。
I would like to begin with a discussion of the amazing and novel technology that sits at the core of everything we do at Pulse Biosciences, our proprietary nanosecond pulsed field ablation, or nsPFA technology. By delivering electric pulses in only billionths of a second durations paired with high energy, we are able to treat tissue non-thermally and with exceptional effectiveness. This translates into tangible and measurable advantages across a range of different diseases and tissues in the human body.
我想先從一項令人驚豔且創新的核心技術談起,這項技術是 Pulse Biosciences 所有工作的基礎:我們專有的奈秒脈衝電場消融技術(nanosecond pulsed field ablation,簡稱 nsPFA)。透過在僅十億分之一秒的時間尺度內輸送電脈衝並搭配高能量,我們能以非熱方式治療組織,且具備卓越的有效性。這可在人體多種不同疾病與組織上,轉化為具體且可衡量的優勢。
nsPFA produces targeted energy, non-thermal ablations, durable lesions, quicker ablation times, and faster procedure times, all complementing the natural body function of regulated cell death. This mechanism is uniquely stimulated by nsPFA and is unmatched by existing ablation energies, including all prior art and the broad category of microsecond PFA alternatives.
nsPFA 可產生具針對性的能量、非熱消融、持久的病灶、更短的消融時間與更快的手術時間,同時也與人體自然的「受調控細胞死亡」功能相互配合。此一機制由 nsPFA 獨特地加以誘發,且是現有消融能量(包括所有既有技術以及廣義的微秒級 PFA 替代方案)所無法比擬的。
Underpinning the platform are a uniquely experienced technology development team, which has produced the highly novel nsPFA system and a deep patent estate of more than 250 issued patents worldwide. Together, this team, a number of whom have worked together for over a decade, and patent moat, are fundamental to protecting and amplifying our long-term leadership in this field.
支撐此平台的是一支具備獨特且豐富經驗的技術開發團隊,他們打造了高度創新的 nsPFA 系統,並建立了深厚的專利布局,在全球已取得超過 250 件已核准專利。這個團隊(其中多位成員已合作超過十年)與專利護城河,對於保護並強化我們在此領域的長期領導地位至關重要。
Last quarter, we announced a strategic alignment to prioritize, accelerate, and broaden the development of our nPulse Cardiac Catheter Ablation System. Our focus remains concentrated on the treatment of atrial fibrillation and the development of our nPulse Cardiac Catheter Systems while we continue to advance our surgical clamp and thyroid programs with discipline and optimism.
上一季,我們宣布進行策略性調整,以優先、加速並擴大我們 nPulse 心臟導管消融系統的開發。我們的重點仍聚焦於心房顫動的治療,以及 nPulse 心臟導管系統的研發;同時,我們也將以嚴謹且樂觀的態度持續推進外科夾鉗與甲狀腺專案。
As part of our strategic alignment, we focused on two key pillars in our program, generating compelling clinical data and executing rapid trial enrollment across a growing base of studies. During the second quarter, with this shift in focus, we have delivered positive and important achievements in our Cardiac Catheter Program. We enrolled the first patient in our pivotal catheter IDE study, including seven cases on day one.
作為策略性調整的一部分,我們聚焦於計畫中的兩大關鍵支柱:產出具說服力的臨床數據,以及在不斷擴大的研究基礎上快速推進試驗收案。在第二季,隨著此一重點轉移,我們在心臟導管計畫上交出了正面且重要的成果。我們在關鍵性導管 IDE 研究中納入了首位受試者,且在第一天就完成七例手術。
We activated multiple sites, presented outstanding feasibility data at the Heart Rhythm Society meeting in April, and further strengthened our leadership team with the additions of Liane Teplitsky as Chief Operating Officer and Dr. David Kenigsberg as full-time Chief Medical Officer. These two leaders have strengthened our ability to execute a successful pivotal IDE study and advance toward regulatory approvals.
我們啟動了多個研究中心,並於四月的 Heart Rhythm Society 年會上發表了出色的可行性數據;同時也透過任命 Liane Teplitsky 擔任營運長,以及聘請 David Kenigsberg 醫師擔任全職醫務長,進一步強化了領導團隊。這兩位領導者提升了我們成功執行關鍵性 IDE 研究並推進監管核准的能力。
We also meaningfully bolstered our balance sheet now with over $100 million on hand, expanding our runway to fund development and clinical milestones ahead. Our financing progress was an important marker of external confidence in Pulse Biosciences. Through our at-the-market, or ATM, program, we raised a total of $57.5 million in net proceeds to date, initiated with continued insider support of approximately $13 million, and the remaining portion coming from outside institutional investors.
我們也顯著強化了資產負債表,目前手上現金超過 1 億美元,延長了我們用以支持後續研發與臨床里程碑的資金跑道。我們在融資方面的進展,是外部對 Pulse Biosciences 信心的重要指標。透過我們的隨市發行(at-the-market,ATM)計畫,截至目前我們已累計募集 5,750 萬美元的淨收益;其中約 1,300 萬美元來自內部人士持續支持,其餘則來自外部機構投資人。
This strengthened our balance sheet during the quarter and reflects growing and expanding conviction in the nsPFA platform and the growth opportunities in front of us. This is a complex environment for raising capital, and we are proud that investors who took a close look at our technical and clinical progress were able to appreciate the value creation story we are building at Pulse Biosciences.
這在本季強化了我們的資產負債表,也反映市場對 nsPFA 平台以及我們面前成長機會的信念正持續提升並擴大。在當前募資環境相當複雜的情況下,我們很自豪能讓仔細檢視我們技術與臨床進展的投資人,理解我們在 Pulse Biosciences 正在打造的價值創造故事。
Additionally, we recently announced that we have surpassed the halfway point of enrollment in our US pivotal catheter study ahead of our original schedule, and on the strength of that pace, we are confident in completing enrollment on our accelerated timeline of early Q4. Reaching this point so quickly in a pivotal AFib study is extraordinary, and we attribute it partly to a straightforward dynamic. Physicians are thrilled by their personal nsPFA clinical experience when using this catheter and are highly enthusiastic to both expand their use and share their positive experiences with their peers. This response is universal across operators.
此外,我們近期宣布,美國關鍵性導管研究的收案已超過一半,且進度早於原先時程;憑藉這樣的速度,我們有信心在加速後的時程(第四季初)完成收案。在一項關鍵性的心房顫動(AFib)研究中如此快速達到此一進度非常罕見,我們認為部分原因來自一個直接的動態。醫師在使用此導管時,對其 nsPFA 的臨床親身體驗感到非常振奮,並高度熱衷於擴大使用,同時也願意與同儕分享正面的使用經驗。這樣的回饋在各位操作者之間普遍一致。
Today I will focus most of my remarks on the catheter and then we'll provide updates on our two other nsPFA devices. We will then turn the call over to our Chief Financial Officer, Jon Skinner, to review the second quarter financial results in detail. We will then conclude with a question and answer session joined by Bob Duggan, Co-Chair of the Board.
今天我將把大部分發言重點放在導管產品,接著我們也會更新另外兩項 nsPFA 裝置的進展。之後我們將把電話交給財務長 Jon Skinner,詳細說明第二季財務結果。最後,我們將進行問答環節,並由董事會共同主席 Bob Duggan 一同參與。
I will now discuss the nPulse Cardiac Catheter System for AF ablation. Earlier in July, we shared that the NANOPULSE-AF study crossed its enrollment midpoint with more than 82 evaluable patients, net of roll-ins, treated in the IDE since the study began enrolling in April. The pace exceeds all expectations and reflects investigational site enthusiasm for what nsPFA technology offers. Durable pulmonary vein isolation, familiar and rapid workflow, intuitive user experience, an efficient procedure, and consistently positive outcomes for patients in need of AFib resolution.
接下來我將討論用於心房顫動(AF)消融的 nPulse 心臟導管系統。在七月稍早,我們分享 NANOPULSE-AF 研究自四月開始收案以來,IDE 研究中已治療超過 82 位可評估患者(扣除 roll-ins),並已跨越收案中點。此一速度超出所有預期,反映研究中心對 nsPFA 技術所帶來價值的高度熱忱。包括持久的肺靜脈隔離、熟悉且快速的工作流程、直覺的使用者體驗、高效率的手術流程,以及對需要解決 AFib 的患者而言一貫正向的治療結果。
We are proud of current results and, rest assured, we are persistent in striving to do even better. Given our enrollment cadence thus far and expectations for site performance in the second half of the study, we are confirming our target completion date of early October, three months earlier than our original timeline. This enrollment velocity reflects the quality of our investigational sites, along with their lab and clinical research staffs, and the compelling clinical attributes of our catheter and energy system.
我們對目前的成果感到自豪,並請放心,我們將持續努力,力求做得更好。鑑於迄今的入組節奏以及對研究下半年各中心表現的預期,我們確認目標完成日期為10月初,較原先時程提前三個月。此入組速度反映了我們研究中心的品質,以及其實驗室與臨床研究團隊的實力,並凸顯我們導管與能量系統具備引人注目的臨床特性。
Physicians comment that the system is extremely intuitive, with a straightforward learning curve, as well as seamless workflow integration, translating directly to rapid, efficient procedure and ablation times. We have seen multiple sites perform five and up to seven cases in a day, and multiple physicians have completed their initial cases with seven to eight minutes or faster ablation times.
醫師回饋該系統極為直覺,學習曲線明確且平順,並可無縫整合至工作流程,直接轉化為快速且高效率的手術與消融時間。我們已看到多個中心一天可完成五例、甚至多達七例;亦有多位醫師在初始病例中達到七到八分鐘或更快的消融時間。
With other ablation catheters currently available, EP labs generally do not schedule more than two to three cases per day. This early on meaningful expansion of daily case capacity is the best evidence of the workflow and procedure speed advantages as well as potential hospital economies that will follow as they utilize the nPulse system.
使用目前其他可得的消融導管時,電生理(EP)實驗室通常每天不會排程超過兩到三例。這種在早期即出現的每日病例量顯著擴增,是工作流程與手術速度優勢的最佳證據,也顯示醫院在使用 nPulse 系統後可能帶來的經濟效益。
Catheters that change practice patterns for the better, and dramatically so in our view, will become a compelling and welcomed option for electrophysiologists and hospitals. Upon the basis of workflow efficiencies, patient outcomes, and more, our nsPFA console and catheters continue to demonstrate unprecedented potential to transform the treatment landscape for atrial fibrillation.
在我們看來,能夠改善、且大幅改善臨床作業模式的導管,將成為電生理醫師與醫院極具吸引力且受歡迎的選擇。基於工作流程效率、病人預後等多項因素,我們的 nsPFA 主機與導管持續展現前所未有的潛力,可望改變心房顫動的治療版圖。
We chose to amend our NANOPULSE-AF pivotal study protocol to increase the total enrollment target by 19 patients from a target of 145 to a new target of 164. This is being done in concert with reducing prior enrollment restrictions on the types of antiarrhythmic drugs, or AADs, a patient must fail in order to qualify for inclusion.
我們選擇修訂 NANOPULSE-AF 關鍵性研究(pivotal study)方案,將總入組目標增加19名患者,從原先目標145名提高至新的目標164名。此舉同時搭配放寬先前對抗心律不整藥物(antiarrhythmic drugs,AADs)種類的入組限制,也就是患者為符合納入條件所需「治療失敗」的藥物類型限制。
Now, patients that have failed any one of the four classes of AADs may qualify for the study. We believe this protocol modification better reflects contemporary clinical practice and real-world patient management. This protocol change also expands the pool of qualifying patients. We are pleased to confirm that full study enrollment is still expected to be completed by our revised date of early October, even with the increase in study size.
現在,凡對四類 AADs 中任一類治療失敗的患者,即可能符合本研究資格。我們相信此方案修訂更能反映當代臨床實務與真實世界的病人管理方式。此方案變更亦擴大了符合資格的患者來源。我們很高興確認,即使研究規模增加,仍預期可在修訂後的10月初如期完成全數入組。
Site activation continues to proceed well, and the momentum across our investigational network is being maintained as we expanded the base of active study sites to 12, and this number is expanding in real time. While the study protocol allows for enrollment at up to 30 sites, we do not anticipate activating all 30 due to the physician enthusiasm and enrollment velocity we have already experienced in the current base as sites and investigators are activated.
研究中心啟動(site activation)持續進展順利;隨著我們將已啟動的研究中心擴增至12家,且此數量仍在即時增加,我們整體研究網絡的動能得以維持。雖然研究方案允許最多可在30個中心入組,但基於目前已啟動中心與研究者所展現的醫師熱忱與入組速度,我們預期不需要啟動全部30個中心。
Diving further into our study protocol, our efficacy endpoint, freedom from treatment failure through 12 months, incorporates a mix of both 12-month and 6-month patient follow-up data. The blended endpoint optimizes overall follow-up time for the study while supporting statistical rigor.
進一步說明研究方案,我們的有效性終點(efficacy endpoint)為12個月內無治療失敗(freedom from treatment failure through 12 months),其納入12個月與6個月的病人追蹤資料之混合。此混合終點在維持統計嚴謹性的同時,也能最佳化整體研究的追蹤時間。
As a reminder of our data presented at Heart Rhythm Society, or HRS, Dr. Vivek Reddy, the National Principal Investigator for our pivotal study, shared expanded results from our European nPulse Cardiac Catheter feasibility study, including 6-month follow-up on 95 patients and 12-month follow-up on 53 patients within the five-second ablation cohort. These data were outstanding.
提醒各位,我們在心律學會(Heart Rhythm Society,HRS)所發表的資料中,本關鍵性研究的全國主要研究者(National Principal Investigator)Vivek Reddy 醫師分享了歐洲 nPulse 心臟導管可行性研究的擴增結果,包括五秒消融隊列中95名患者的6個月追蹤,以及53名患者的12個月追蹤。這些數據表現非常出色。
100% freedom from AF measured by 24-hour Holter monitor at six months and 96% as measured by 24-hour Holter monitor at one year, along with 90% Kaplan-Meier estimated freedom from recurrent AF, flutter, or tachycardia at one year, alongside a serious adverse event rate of just 1.7% across 177 patients. Those numbers compare quite favorably to the meaningfully lower success rates typically seen with other ablation technologies and were achieved without antiarrhythmic drugs and with consistent performance across operators and sites. The EU feasibility data continue to support our path toward a CE Mark submission in the second half of this year, and we see a potential CE approval around the middle of 2027, roughly six months post-submission.
以24小時霍爾特(Holter)監測衡量,6個月時心房顫動(AF)無復發率為100%,1年時為96%;同時,Kaplan-Meier 估計1年時無復發 AF、心房撲動(flutter)或心動過速(tachycardia)的比例為90%;此外,在177名患者中嚴重不良事件率僅1.7%。相較於其他消融技術通常可見的顯著較低成功率,這些數字具備相當優勢;且是在未使用抗心律不整藥物的情況下達成,並在不同操作者與中心間呈現一致表現。歐盟可行性研究數據持續支持我們於今年下半年提交 CE 認證(CE Mark)申請的路徑;我們預期 CE 核准可能落在2027年年中左右,約為提交後六個月。
Supporting our go-to-market strategy with the EP catheter, we are continuing to pursue a partnership strategy. Our dialogue with prospective partners is ongoing, centered around the established players in electrophysiology with available mapping technologies. Those conversations are underway and we'll provide details when appropriate.
為支持我們以 EP 導管推進上市(go-to-market)策略,我們持續採取合作夥伴策略。我們與潛在合作夥伴的對話仍在進行中,重點聚焦於電生理領域中已具規模、且擁有既有定位(mapping)技術的業者。相關洽談正在推進,適當時機我們將提供更多細節。
Let's now move to our surgical clamp program, where treatments in our pivotal IDE clinical study continue to perform well. Concomitant ablation for pre-existing AF is, in our view, significantly underpenetrated, and we believe nanosecond PFA can support increased surgeon adoption and drive meaningful market penetration over time.
接著談到我們的外科夾鉗(surgical clamp)計畫,我們在關鍵性 IDE 臨床研究中的治療表現持續良好。在我們看來,針對既存 AF 的合併消融(concomitant ablation)滲透率仍明顯不足;我們相信奈秒級 PFA 可支持更多外科醫師採用,並隨時間推進帶動具意義的市場滲透。
Currently available tools provide inconsistent results with involved and time-consuming procedure protocols. Our clamp was designed to address these needs efficiently and to deliver the speed and effectiveness of nsPFA technology, which is capable of delivering reproducible transmural lesions nearly instantaneously, producing a more reliable and trusted ablation procedure, all for the purpose of improved patient outcomes.
目前可用的工具結果不一致,且手術流程繁複、耗時。我們的夾鉗設計旨在有效滿足這些需求,並提供 nsPFA 技術的速度與效能;該技術可近乎瞬間產生可重現的全層(transmural)病灶,帶來更可靠、值得信賴的消融流程,最終目的在於改善病人預後。
In addition to our IDE enrollment, our EU feasibility study has now treated more than 70 patients across six sites. Three-month post-procedure electroanatomical mapping results were presented at the European Heart Rhythm Association 2026 meeting and demonstrated excellent lesion durability and procedural efficacy on 34 patients.
除 IDE 入組外,我們的歐盟可行性研究目前已在六個中心治療超過70名患者。術後三個月的電解剖定位(electroanatomical mapping)結果已於2026年歐洲心律協會(European Heart Rhythm Association)年會發表,並在34名患者中顯示優異的病灶持久性與手術有效性。
Total ablation time averaged just 41 seconds per patient. And pulmonary vein isolation success held steady at an extremely high rate of 94% at the three-month follow-up, unchanged from the initial readout we provided in October of 2025. Just as telling is the qualitative feedback. Surgeons consistently praised the speed, lesion quality, and ease of use provided by the Pulse nsPFA clamps. Given this encouraging progress, we remain on schedule to file for CE Mark before the end of 2026.
每位患者的總消融時間平均僅41秒。且在三個月追蹤時,肺靜脈隔離(pulmonary vein isolation)成功率仍維持在極高的94%,與我們在2025年10月提供的初步讀出結果一致、未見變化。同樣具指標性的是質性回饋。外科醫師一致稱讚 Pulse nsPFA 夾鉗所帶來的速度、病灶品質與易用性。基於這些令人鼓舞的進展,我們仍按計畫在2026年底前提交 CE 認證申請。
In the US, our pivotal study, NANOCLAMP AF, continues to enroll. As a reminder, it remains the only trial of a PFA surgical device to have secured FDA IDE approval. The IDE is a prospective single-arm study spanning 20 centers, three of them international, with a target of 136 patients designed to establish the safety and effectiveness of the nPulse Cardiac Catheter System in treating AF during concomitant cardiac surgery.
在美國,我們的關鍵性研究 NANOCLAMP AF 持續入組。提醒各位,該研究仍是唯一獲得 FDA IDE 核准的 PFA 外科裝置試驗。此 IDE 為前瞻性單臂研究,涵蓋20個中心,其中3個為國際中心;目標入組136名患者,旨在於合併心臟手術期間治療 AF,以建立 nPulse 心臟導管系統的安全性與有效性。
Enrollment and site activation is progressing, and we expect to complete enrollment by the end of the first half of 2027. Turning to our nPulse Vybrance Percutaneous Electrode System, the nPulse Vybrance System uses our nanosecond PFA technology to ablate soft tissue percutaneously. Vybrance can be used to ablate symptomatic benign thyroid nodules as an alternative to full thyroidectomy surgery.
入組與中心啟動正持續推進,我們預期將於2027年上半年末完成入組。接著談到我們的 nPulse Vybrance 經皮電極系統(Percutaneous Electrode System),nPulse Vybrance 系統使用我們的奈秒級 PFA 技術,以經皮方式消融軟組織。Vybrance 可用於消融具症狀的良性甲狀腺結節,作為全甲狀腺切除手術的替代方案。
Rather than removing tissue unnecessarily, Vybrance treats the thyroid through a minimally invasive approach in the outpatient setting. The procedure shrinks the nodule and relieves symptoms while sparing the surrounding anatomy and preserving thyroid function, a highly desirable outcome that is not possible with traditional surgical excision of the thyroid.
Vybrance 並非不必要地切除組織,而是在門診環境中以微創方式治療甲狀腺。該手術可使結節縮小並緩解症狀,同時保留周邊解剖結構並維持甲狀腺功能;這是一項極為理想的結果,而傳統的甲狀腺外科切除無法達成。
In the second quarter, Vybrance's disposable sales were $434,000, a sequential increase from $400,000 in the first quarter. We remain focused on core market development goals, including generating clinical data for both expanding reimbursement coverage and achieving specific regulatory label claims. We are proud to announce a new partnership with the Clayman Thyroid Center in Tampa, Florida, the largest thyroid surgery center in the United States. This unique partnership is focused on supporting our core strategy of demonstrating the viability of the Vybrance system therapy for patients with symptomatic benign thyroid nodules. Key elements of this partnership will include registry data generation and unique study protocols for interventional therapy in thyroid disease.
第二季,Vybrance 的一次性耗材銷售額為 434,000 美元,較第一季的 400,000 美元呈現季增。我們仍專注於核心市場開發目標,包括產出臨床數據,以同時支持擴大給付/報銷覆蓋範圍並取得特定的監管標示(label)主張。我們很榮幸宣布與佛羅里達州坦帕的 Clayman 甲狀腺中心建立新的合作夥伴關係,該中心為美國最大的甲狀腺手術中心。此一獨特合作聚焦於支持我們的核心策略:證明 Vybrance 系統療法對於有症狀的良性甲狀腺結節患者之可行性。此合作的關鍵要素將包括登錄研究(registry)數據產出,以及針對甲狀腺疾病介入治療的獨特研究方案。
Bringing on a center of this caliber is an important step toward our goal of establishing nsPFA as a minimally invasive standard of care for benign thyroid nodules. Over the past several weeks, the Clayman Center has onboarded the Vybrance system and performed its first cases, and we look forward to reporting on progress toward our partnership objectives in future quarters.
引進如此等級的中心,是我們朝向將 nsPFA 建立為良性甲狀腺結節微創標準照護的重要一步。在過去幾週,Clayman 中心已完成 Vybrance 系統導入並執行首批病例;我們期待在未來季度報告合作目標的進展。
Additionally, our PRECISE-BTN, benign thyroid nodule study, continues to proceed quickly, and we expect the study to be fully enrolled this month. We broadened the study from its original 50-patient design to 100 patients to deepen the data set in support of adoption and long-term market expansion. Scientific recognition of this work continues to grow.
此外,我們的 PRECISE-BTN 良性甲狀腺結節研究持續快速推進,並預期本月完成全數收案。我們已將研究從原先 50 名患者的設計擴大至 100 名患者,以加深數據集,支持採用推廣與長期市場擴張。此項工作的科學界認可度持續提升。
Data from Dr. Stefano Spiezia in Naples, Italy, was recently presented in a podium session at the North American Society of Interventional Thyroidology, or NASIT. The data showed durable results out to 15 to 22 months, a 74% reduction in treated nodule volume as per our expectations, alongside overwhelming patient satisfaction, featuring very rapid symptoms relief post-treatment. Volume reduction continued to improve from one month all the way through 22 months with no nodule regrowth observed in the 15 to 22-month time frame.
義大利那不勒斯的 Stefano Spiezia 醫師之數據近期在北美介入甲狀腺學會(North American Society of Interventional Thyroidology,NASIT)的口頭報告場次中發表。數據顯示療效可持續至 15 至 22 個月;治療結節體積降低 74%,符合我們的預期,同時患者滿意度極高,治療後症狀緩解非常迅速。體積縮小自 1 個月起一路改善至 22 個月,且在 15 至 22 個月期間未觀察到結節再生長。
Beyond PRECISE-BTN, we are also widening the clinical scope of our Vybrance platform. Through our research collaboration with the University of Texas MD Anderson Cancer Center, researchers at two study centers are conducting a multi-center, first-in-human feasibility study of nsPFA for papillary thyroid microcarcinoma, or PTMC. This study is designed to enroll up to 30 patients across two sites.
除 PRECISE-BTN 之外,我們也在擴大 Vybrance 平台的臨床範疇。透過與德州大學 MD Anderson 癌症中心的研究合作,兩個研究中心的研究人員正在進行 nsPFA 用於乳頭狀甲狀腺微小癌(papillary thyroid microcarcinoma,PTMC)的多中心、首次人體可行性研究。該研究設計為在兩個據點最多收案 30 名患者。
I'm pleased to announce that this study is approximately half enrolled, and we expect to complete enrollment by year-end 2026. And looking ahead, we've begun planning additional clinical trials with the aim of extending the Vybrance platform into new thyroid indications as we support our plans to bring this revolutionary therapy to a broader patient population.
我很高興宣布,該研究目前約已完成一半收案,並預期於 2026 年底前完成收案。展望未來,我們已開始規劃其他臨床試驗,目標是在支持我們將這項革命性療法帶給更廣泛患者族群的同時,把 Vybrance 平台延伸至新的甲狀腺適應症。
With that, I'll turn the call over to Jon to walk through our second quarter financial results.
接下來,我將把電話會議交給 Jon,由他說明我們第二季的財務結果。
Jon Skinner - Chief Financial Officer
Jon Skinner - Chief Financial Officer
Thank you, Paul.
謝謝你,Paul。
Now, I will highlight our GAAP and non-GAAP financial results. I encourage listeners to review today's earnings release for a detailed reconciliation of non-GAAP measures to the most comparable GAAP measures. In the second quarter, we generated revenue of $434,000 and cost of product revenue was $273,000 for the quarter. We remain in a disciplined launch focused on clinical and market development.
現在,我將重點說明我們的 GAAP 與非 GAAP 財務結果。我鼓勵各位聽眾查閱今日的財報新聞稿,以取得非 GAAP 指標與最可比 GAAP 指標之間的詳細調節表。第二季,我們創造營收 434,000 美元,當季產品營收成本為 273,000 美元。我們仍以紀律性的方式推進上市,聚焦於臨床與市場開發。
Based on strong clinical results, we remain focused on growing procedural utilization within a limited customer base. Total GAAP costs and expenses for the quarter increased by $5.4 million to $25.7 million, compared to $20.3 million in the prior year period.
基於強勁的臨床結果,我們仍專注於在有限的客戶基礎內提升手術使用量。本季 GAAP 總成本與費用增加 540 萬美元至 2,570 萬美元,相較於去年同期的 2,030 萬美元。
The increase in GAAP costs and expenses was primarily driven by increased investment in our clinical programs and compensation and employee-related spend supporting our growth in clinical and product development. Compensation and employee-related expenses, including stock-based compensation, increased approximately $2.7 million versus the prior year period. To remind everyone, non-GAAP costs and expenses exclude stock-based compensation, depreciation, and amortization, as well as non-recurring costs.
GAAP 成本與費用的增加,主要來自我們對臨床計畫的投資提升,以及為支持臨床與產品開發成長而增加的薪酬與員工相關支出。包含股票基礎薪酬在內的薪酬與員工相關費用,較去年同期約增加 270 萬美元。提醒各位,非 GAAP 成本與費用不包含股票基礎薪酬、折舊與攤銷,以及一次性/非經常性成本。
Total non-GAAP costs and expenses in the second quarter of 2026 increased by $5.7 million to $20.5 million, compared to $14.8 million in the prior year period. The expected increase was driven by increasing clinical trial expenses and $2.9 million of compensation and employee-related expenses.
2026 年第二季非 GAAP 總成本與費用增加 570 萬美元至 2,050 萬美元,相較於去年同期的 1,480 萬美元。此一預期中的增加主要由臨床試驗費用上升,以及 290 萬美元的薪酬與員工相關費用所驅動。
Looking ahead, we expect quarterly operating expenses to remain in this range on a non-GAAP basis as we continue to invest in our clinical programs. GAAP net loss in the second quarter of 2026 was $24.7 million compared to $19.2 million in the prior year period. Non-GAAP net loss in the second quarter of 2026 was $19.4 million compared to $13.7 million in the prior year period.
展望未來,隨著我們持續投資臨床計畫,我們預期以非 GAAP 口徑計算的季度營運費用將維持在此區間。2026 年第二季 GAAP 淨損為 2,470 萬美元,去年同期為 1,920 萬美元。2026 年第二季非 GAAP 淨損為 1,940 萬美元,去年同期為 1,370 萬美元。
As of June 30, 2026, cash and cash equivalents totaled $101.6 million compared to $68.3 million as of March 31, 2026, representing an increase of $33.3 million versus the prior quarter. Cash used in operating activities during the second quarter of 2026 was $18.7 million compared to $12.8 million used in the prior year period and $14.6 million in Q1 of 2026.
截至 2026 年 6 月 30 日,現金及約當現金合計為 1.016 億美元,相較於 2026 年 3 月 31 日的 6,830 萬美元,較前一季增加 3,330 萬美元。2026 年第二季營運活動使用現金為 1,870 萬美元,相較於去年同期使用的 1,280 萬美元,以及 2026 年第一季的 1,460 萬美元。
Through our ATM program, $57.5 million in net proceeds was raised since May. Bob Duggan and the Pulse team partnered with a sales agent to manage daily participation and run a successful program, raising approximately $44.5 million from outside investors.
透過我們的 ATM 計畫,自 5 月以來已募集 5,750 萬美元的淨募資款。Bob Duggan 與 Pulse 團隊與銷售代理合作,管理每日參與並成功執行該計畫,從外部投資人募集約 4,450 萬美元。
During Q2, insiders announced intent to purchase shares through the ATM program three trading days prior to the insider transaction, and management provided this update during our Q1 earnings call. This continued insider support contributed approximately $13 million through the ATM. Of the $57.5 million in net proceeds, $46.8 million was raised during the second quarter, with an additional $10.7 million raised subsequent to the close of Q2 and thus not included in our reported cash balances.
在第二季,內部人士於內部人交易前三個交易日,透過 ATM 計畫公告其擬購買股份之意向,而管理層亦在我們第一季財報電話會議中提供了此更新。此一持續的內部人士支持,透過 ATM 貢獻約 1,300 萬美元。在 5,750 萬美元的淨募資款中,第二季募集 4,680 萬美元;另有 1,070 萬美元於第二季結束後募集,因此未納入我們所報告的現金餘額。
As a result, we strengthened our balance sheet, ending with a stronger cash position than we began and extending our runway to the key clinical and regulatory milestones ahead. Additionally, we put a new $75 million ATM facility in place to preserve our financing flexibility going forward, along with our shelf that was put in place in February.
因此,我們強化了資產負債表,期末現金部位較期初更為充裕,並將資金可支撐期間(runway)延長至前方關鍵的臨床與監管里程碑。此外,我們也新設立 7,500 萬美元的 ATM 額度,以保留未來融資彈性,並搭配我們於 2 月建立的 shelf(架上發行)註冊。
We also received gross proceeds of $1.8 million related to exercises of the second tranche of 2024 rights offering warrants in July. Following this redemption, there are no remaining warrants outstanding. We remain disciplined on expense growth while continuing to fund our clinical programs, prioritizing financing through key milestones ahead.
我們也在7月收到與2024年權利發行認股權證第二批次行使相關的總募集款項180萬美元。在此次贖回後,已無任何尚未行使的認股權證。我們在持續資助臨床計畫的同時,仍嚴守費用成長紀律,並優先透過融資以支持達成前方關鍵里程碑。
With that, I will now turn it back to Paul for closing remarks.
接下來,我將把時間交還給Paul作結語。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thank you, Jon.
謝謝你,Jon。
Our strategic focus remains the treatment of atrial fibrillation, and with each new data readout, each new site activation, and each new investigator experience, the clinical strength and disruptive market potential of nsPFA becomes clearer to all. Enrollment in our pivotal IDE study is progressing ahead of our original timeline, driven by strong physician demand and site motivation.
我們的策略重點仍聚焦於心房顫動的治療;隨著每一次新的數據讀出、每一個新據點啟用,以及每一位新研究者的使用經驗,nsPFA的臨床優勢與顛覆性的市場潛力對所有人而言都愈發清晰。在強勁的醫師需求與據點動能帶動下,我們關鍵性的IDE研究收案進度已超前原先時程。
Looking ahead, our priorities remain clear. Continuing enrollment of our IDEs, progressing towards CE Mark approvals for our cardiology devices, advancing our catheter partnership discussions, and new this quarter, developing Vybrance market value through our partnership with Clayman Center, all while maintaining the operating discipline required to effectively execute and complete these critical milestones that will define Pulse Biosciences' future.
展望未來,我們的優先事項依然明確。持續推進IDE研究收案、朝心臟科器械取得CE Mark核准邁進、推動導管合作夥伴討論,以及本季新增的重點——透過與Clayman Center的合作提升Vybrance的市場價值;同時維持有效執行並完成這些關鍵里程碑所需的營運紀律,而這些里程碑將界定Pulse Biosciences的未來。
nsPFA technology continues to demonstrate remarkable clinical differentiation, and our work going forward is to transform that platform potential into durable, scaled businesses capable of generating multiple billion dollars of recurring revenue. Thank you for your continued support, and we look forward to updating you again next quarter.
nsPFA技術持續展現卓越的臨床差異化;我們接下來的工作,是將該平台的潛力轉化為可長期維持、可規模化的事業體,並有能力創造數十億美元的經常性收入。感謝各位持續支持,我們期待在下個季度再次向各位更新進展。
Now, joining us for the question and answer session is Bob Duggan, Co-Chairman of the Board. Operator, please open the call for questions.
現在,與我們一同參與問答環節的是董事會聯席主席Bob Duggan。接線員,請開放提問。
Operator
Operator
(Operator Instructions) Bill Plovanic, Canaccord Genuity.
(接線員指示)Canaccord Genuity的Bill Plovanic。
William Plovanic - Analyst
William Plovanic - Analyst
Congratulations on successfully the enrollment rates. My first question pertains to that. You've talked about the combination of the 6- and 12-month data and the final module submission. Given that this enrollment is so fast, I don't think I've seen anything quite this fast, does it even benefit you to have it be a combination of 6- and 12-month data, or is this something where you might end up waiting till you have full 12-month data for the final module submission of the PMA for the NANOPULSE-AF?
恭喜你們成功達成收案速度。我的第一個問題就與此相關。你們談到將6個月與12個月數據結合,以及最終模組提交。鑑於收案如此之快——我想我從未見過這麼快的——把6個月與12個月數據結合對你們是否仍有好處?還是說你們最後可能會等到取得完整12個月數據後,才提交NANOPULSE-AF的PMA最終模組?
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thank you, Bill. Good question, and you're right. So just to be, let's say, level-setting, the 6- and 12-month combination presumes that patients early in enrollment will be followed 12 months, and patients later in enrollment will be followed six months. Then the question becomes, what's the long pole, right? And if you enroll the second half of the study and follow those patients for six months, they might reach their 6-month endpoint before the earlier patients reach 12 months.
謝謝你,Bill。好問題,你說得沒錯。先做個基準說明:6個月與12個月的組合,假設是收案較早的病人會追蹤12個月,而收案較晚的病人會追蹤6個月。接著問題就變成:哪一段是最長的關鍵路徑,對吧?如果你把研究後半段收完並追蹤6個月,這些病人可能在較早收案的病人達到12個月之前,就先達到6個月終點。
So I think the real way to focus, that the -- I'll call it on the absolute timeline, is to think about 12-month follow-up on the patient cohort. And frankly, at that point, if enrollment continues to go so swiftly, whether you set that bar and say, let's do 12-month follow-up on the 80th patient or the 100th patient or the 130th patient, the absolute time differential between those is relatively short.
所以我認為真正的聚焦方式——就我稱之為絕對時程而言——是以該病人隊列的12個月追蹤來思考。坦白說,在那個時間點,如果收案持續如此迅速,無論你把門檻設在第80位、第100位或第130位病人的12個月追蹤,這些之間的絕對時間差其實相對不大。
So we're focused less on that than we are on quality and expedited enrollment. We're very pleased by how enrollment is going. I would say we're very pleased by the uptake of second and third wave sites, and the fact that there's really no distinction between how a new user establishes clinical comfort with our catheter today versus how that was established a few months ago when the IDE commenced or last year when our first in human experience was commenced.
因此,相較於那一點,我們更關注的是品質與加速收案。我們對目前的收案進展非常滿意。我也會說,我們對第二波與第三波據點的採用情況非常滿意;而且事實上,新使用者如今建立對我們導管的臨床熟悉度,與幾個月前IDE啟動時、或去年我們首次人體試驗啟動時相比,並沒有真正的差異。
So very good question. 12 months from the earlier patient group is the long pole in the tent. And despite that, we'll certainly, we're going to be using all tools available to us to manage timelines effectively, including enrollment, including follow-up, and then, of course, submitting very clean data to provide FDA the opportunity to minimize their review time once submitted.
所以這是個很好的問題。較早收案病人群的12個月追蹤,是整體時程中最長的關鍵路徑。儘管如此,我們當然會運用所有可用工具來有效管理時程,包括收案、追蹤;然後,當然也包括提交非常乾淨的數據,讓FDA在收到資料後有機會將審查時間降到最低。
William Plovanic - Analyst
William Plovanic - Analyst
Just a follow-up on that, Paul, is -- given that, I mean, 80 patients out of, you probably had only six or seven accounts that did all of those, I would imagine it's gone so quickly. Do any of these accounts stop out just because they've had too many, you don't want them to get to be too many patients or too big a piece of the study? And so that's maybe why the pacing that you're providing kind of maintaining, even though you expand the number, but maintaining the timeline on this is because some of those earlier sites are going to cap out.
就此再追問一下,Paul——在這樣的情況下,我是說,80位病人中,可能只有六、七個中心就完成了全部收案,我想進度真的很快。這些中心是否會因為收太多而暫停收案,因為你們不希望某個中心的病人數過多、在研究中占比過大?所以這也許就是你們所提供的節奏——即使擴增中心數量,仍維持整體時程——的原因,因為一些較早的中心將會達到上限。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
That also is a great observation. And the typical of all FDA-approved protocols, the FDA is worried about and focused on generating a representative patient pool of data. And in a multi-center study, they want to assure that there is not excessive skew toward one or two centers. And so we do have a cap that represents 15% of patient enrollment at a given site, no more. And I will say in response specifically to your observation, yes, several sites already have met their cap.
這也是一個很好的觀察。依照所有FDA核准的試驗方案慣例,FDA會擔心並著重於產生具代表性的病人資料池。在多中心研究中,他們希望確保資料不會過度偏向一、兩個中心。因此,我們確實設有上限:單一據點的收案不得超過總收案的15%。針對你剛才的觀察,我可以具體回應:是的,已有數個據點達到其上限。
Now, of course, the next sites being opened are equally interested in enrolling as many patients as they can. But as is always the case with clinical trial management, one, the sponsor, in this case, Pulse Biosciences, can't specifically predict which next site will be the next site to enroll very rapidly and to reach its cap.
當然,接下來開放的據點同樣非常有興趣盡可能多收案。但如同臨床試驗管理一貫的情況,贊助方——在此為Pulse Biosciences——無法明確預測下一個據點中,哪一個會迅速開始大量收案並達到其上限。
So our job is to continue to activate sites, which we're doing. We have more in the queue, and we'll activate more sites over the next one and two months, and we'll continue to do that up to the point where we are nearing final enrollment. But, yes, some of the measured momentum throughout now and the next several months toward our expected completion date is regulated, if you will, by the turnover of high-performing sites as we cap out on some and as new ones emerge to become the next high-volume enrollers.
因此,我們的工作就是持續啟用據點,而我們正在這麼做。我們還有更多據點在排程中,並將在未來一到兩個月啟用更多據點;我們也會持續這樣做,直到接近最終收案為止。不過,是的,從現在到未來幾個月,朝向我們預期完成日期的部分可衡量動能,在某種程度上可說會受到高績效據點輪替的「調節」:一些據點達到上限後退出,而新的據點崛起成為下一批高量收案中心。
William Plovanic - Analyst
William Plovanic - Analyst
And then last one, I promise, is just, you expanded the study. So my question was any major learnings, you've enrolled 80 patients, but any major learnings from those 80 patients, and it sounds like one of them is just, hey, let's make sure we have all the AADs and get a real-world patient population, but I don't want to put words in your mouth.
最後一個問題,我保證:你們擴大了研究規模。所以我想問的是,在已收案的80位病人中,有沒有任何重大的學習或洞見?聽起來其中之一可能是:嘿,確保納入所有AADs,並取得更貼近真實世界的病人族群——但我不想替你們下結論。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thank you, Bill. Well, I won't comment on any form of results, but as we've indicated in our message about both the rapidity of enrollment and all the way back to our first announcement of first patient in. This is a -- it's an exciting trial. Physicians are extremely enthusiastic about this technology. As you know, I've been doing clinical trials for 40 years, cardiovascular breakthrough clinical trials for probably 35 years.
謝謝你,Bill。嗯,我不會評論任何形式的結果;但如同我們在訊息中所指出的,無論是關於收案速度,或回溯到我們首次宣布首位病人入組時。這是一項——令人振奮的試驗。醫師對這項技術極為熱情。如你所知,我做臨床試驗已有40年,其中心血管突破性臨床試驗大概有35年。
I've never seen trial enthusiasm any stronger than what we have here. And so we're just amazed by -- and I actually had this conversation with several members of our team, that as we focus on the extraordinary data, the outcomes, the data set that we announced at HRS, unprecedented data, it's important for us not to take for granted the acute experience in the lab.
我從未見過比我們在這裡所看到的更強烈的試驗熱情。因此,我們對此感到非常驚訝——而且我其實也和我們團隊的幾位成員談過:當我們聚焦於這些非凡的數據、結果,以及我們在 HRS 公布的數據集(前所未有的數據)時,對我們而言很重要的一點是,不要把實驗室中的急性操作體驗視為理所當然。
If we think about the AFib market, if we think about the dynamic change, the disruptive change that new technologies have brought in the last year, the shifts in market share, how those shifts in market share have translated to really fundamental shifts in market leadership positions, that has all been principally driven without outcomes data differences and mostly based on acute experience in the lab. And so the acute experience in the lab we have been clear about, we have been transparent about.
如果我們思考房顫(AFib)市場,思考動態變化、以及新技術在過去一年帶來的顛覆性變化,市占率的移轉,以及這些市占率移轉如何轉化為市場領導地位的根本性變化——這一切主要是在沒有結局(outcomes)數據差異的情況下被推動的,而且多半是基於實驗室中的急性操作體驗。因此,對於我們在實驗室中的急性操作體驗,我們一直說得很清楚,也一直保持透明。
That acute experience in the lab is unbelievable. Rapid learning curve. Almost no required time to become facile with our catheter. Extremely rapid procedure times based principally on a limited number of ablations required because of the clarity and power of our lesions, and extremely short lesion delivery times of five seconds. So when you piece those together, the physicians who are the crème de la crème are telling us that this is an experience they've never had before.
那種在實驗室中的急性操作體驗令人難以置信。學習曲線非常快。幾乎不需要花時間就能熟練使用我們的導管。手術時間極為迅速,主要原因是所需消融次數有限,因為我們病灶的清晰度與能量效果很強,而且單次病灶傳遞時間極短,只有五秒。所以當你把這些因素拼在一起,那些頂尖中的頂尖醫師(crème de la crème)告訴我們,這是他們從未有過的體驗。
And I think while it's not data, it's observation and it's anecdotal, but I think the biggest learning is the validation of the fact that the Pulse Biosciences catheter experience in the lab is something unlike they've ever experienced before. That is a telling marker for how this technology is likely to be adopted when it becomes available.
我認為,雖然這不是數據,而是觀察與軼事,但我覺得最大的收穫在於:驗證了 Pulse Biosciences 的導管在實驗室中的操作體驗,確實是他們從未經歷過的。這是一個很有指標性的訊號,顯示當這項技術一旦可用時,很可能會如何被採用。
Robert Duggan - Independent Co-Chairman of the Board
Robert Duggan - Independent Co-Chairman of the Board
Paul, this is Bob. If I just might add something to Bill here.
Paul,我是 Bob。如果我可以在 Bill 的基礎上補充一點。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Please, Bob.
請說,Bob。
Robert Duggan - Independent Co-Chairman of the Board
Robert Duggan - Independent Co-Chairman of the Board
Thank you. The faster enrollment is really a very positive product function feature as it's easy to use, as we found out. The quantity of patients treated is a very positive product economic feature for the OR. It is OR ROI that is significant. So we're really pleased about both of them, both the economics, which ultimately are the adjudicator of hospital take-up if in fact the product is giving you superior results on the patient side.
謝謝。更快的收案速度其實是一個非常正面的產品功能特徵,因為它很容易使用——我們已經發現了。治療的病患數量是一個對手術室(OR)而言非常正面的產品經濟特徵。手術室的投資報酬率(OR ROI)很關鍵。因此,我們對這兩點都非常滿意——包括經濟性;而經濟性最終會成為醫院是否採用的裁決因素,前提是產品在病患端確實帶來更優異的結果。
So we look forward to the patient side, we're very confident, but we're very pleased about the quantity of patients being treated, and it wasn't something that we pushed or promoted. It was just the doctors went look, I've got more time here. I'm done with the three in a few hours, and I did stack up some patients, and we'll just bring them all through. So it's a double positive. We're really pleased with that.
所以我們期待看到病患端的表現,我們非常有信心;同時,我們也很高興看到被治療的病患數量,而這並不是我們去推動或宣傳的。只是醫師們說:你看,我這裡有更多時間。我在幾個小時內就完成三位了,我就把一些病患排進來,然後把他們都做完。所以這是雙重利多。我們對此非常滿意。
Operator
Operator
Anthony Petrone, Mizuho Group.
Mizuho Group 的 Anthony Petrone。
Anthony Petrone - Analyst
Anthony Petrone - Analyst
And congrats here on the progress on the IDE study. Maybe, Paul and/or Bob, just one on just mapping integration. In the last, at HRS, we talked about nPulse magnet being compatible with Abbott's EnSite. I think the messaging there was that CARTO was going to be brought into the study. So in the IDE, are we still only using EnSite?
也恭喜 IDE 研究的進展。也許 Paul 和/或 Bob,我想問一個關於電生理標測(mapping)整合的問題。上次在 HRS,我們談到 nPulse 磁體與 Abbott 的 EnSite 相容。我記得當時的訊息是 CARTO 會被納入研究。所以在 IDE 中,我們是否仍然只使用 EnSite?
Have you brought in CARTO at this point? And maybe can you recap, what do you think continuous mapping can do, you know, ultimately for results when you compare it just to the IDE or the EFS study where we just used fluoro? And I'll have one quick follow-up.
你們目前已經把 CARTO 納入了嗎?另外也許你可以回顧一下:你認為連續標測(continuous mapping)最終在結果上能帶來什麼改善——相較於 IDE 或 EFS 研究中我們只使用透視(fluoro)的情況?我還有一個很快的追問。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thank you, Anthony. Yes, so the study has been enrolled to date with EnSite. We've been clear about that. You're commenting on physician commentary coming out of, I think, HRS where in some of those panel discussions, physicians, I would say, speculated about the potential for results to potentially even improve with higher quality integration of how our catheter is represented on the mapping system. And so I would say we expect to see that manifested.
謝謝你,Anthony。是的,截至目前本研究的收案都是使用 EnSite。我們一直很清楚地說明這點。你提到的是我想在 HRS 的一些座談討論中,醫師們的評論;我會說,他們是在推測:如果我們的導管在標測系統上的呈現方式能有更高品質的整合,結果可能甚至還會進一步改善。因此,我會說我們預期會看到這樣的效果呈現出來。
And I will say, if you think about more sites picking up the technology for the first time, treating patients, and you measure, I think, your question by the efficiency of the procedure. How many ablations were needed? And you can't compare specifically the IDE to feasibility because the feasibility study contained a little bit more patient heterogeneity, some additional ablation strategies were deployed.
另外我也想說,如果你思考更多中心第一次採用這項技術、開始治療病患,而你用手術效率來衡量你的問題——需要多少次消融?你無法把 IDE 和可行性(feasibility)研究做直接比較,因為可行性研究的病患異質性更高一些,也採用了額外的一些消融策略。
But if you look at the IDE, the number of ablations per case is quite limited, quite efficient. And that's a measure of physician confidence in their specific placement of the catheter in the anatomy. And of course, they deliver that limited lesion set, and then they do a post-anatomical map, and they can record specifically the effectiveness in the lab of that lesion set. And so the ability to have tight integration translates to limited lesion numbers while achieving acute isolation, and that's the goal.
但如果你看 IDE,每個病例的消融次數相當有限、效率很高。這反映了醫師對於導管在解剖結構中精準放置的信心。當然,他們施作那一組有限的病灶後,會再做一次術後解剖標測,並能在實驗室中具體記錄那組病灶的有效性。因此,更緊密的整合能力,能在達成急性隔離(acute isolation)的同時,轉化為更少的病灶數量,而這就是目標。
So I do think we see a clear result of tighter integration. And we won't comment further on any changes in the mapping systems being used, but I will confirm that through today, and while we have the ability to use other mapping systems, all of the cases have been done with the EnSite system.
所以我確實認為我們看到了更緊密整合所帶來的明確效果。至於所使用的標測系統是否有任何變更,我們不會進一步評論;但我可以確認,截至今天,雖然我們具備使用其他標測系統的能力,所有病例都是使用 EnSite 系統完成的。
Anthony Petrone - Analyst
Anthony Petrone - Analyst
No, it's helpful. And the follow-up here would be on capitalization. You brought some more capital in. The cost of the trials here is going higher. But we are getting to a point it is enrolling faster.
不,這很有幫助。那我這裡的追問是關於資本化(capitalization)。你們引入了更多資金。這些試驗的成本正在上升。但我們也正走到一個收案更快的階段。
You're looking into 2027. Almost presumably, you could be on a footing for a launch. Today as well, you announced on track for CE Mark submission. So does the capital also contemplate building up the infrastructure, you know, perhaps even on the direct sales side, where does the capital bring you? Is it just through clinical trial development, or will you actually start market development as well?
你們展望到 2027 年。幾乎可以推測,你們可能已經具備上市(launch)的基礎。同時,你們也宣布 CE Mark 送件進度如期。所以這筆資金是否也包含建立基礎設施,例如甚至在直銷團隊方面的擴建?資金會把你們帶到哪裡?它只是用於臨床試驗開發,還是你們也會開始市場開發?
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thank you, Anthony. Go ahead, Bob.
謝謝你,Anthony。Bob,你先請。
Robert Duggan - Independent Co-Chairman of the Board
Robert Duggan - Independent Co-Chairman of the Board
Yes. I've had my finger on the pulse of that. Away from the pre-announcement that Paul and I made and gave other investors three days to jump in front of us if they desired to, the balance of the money was raised in the 27-28 area, which is about where we closed out the quarter. So we were pleased with our patience and how that went.
好的。我一直密切掌握這件事。撇開 Paul 和我在事前公告(pre-announcement)之外——我們也給了其他投資人三天時間,如果他們願意的話可以在我們之前參與——其餘資金是在 27-28 的區間募集到的,這大約就是我們該季收盤的水準。所以我們對於我們的耐心以及整個過程的結果感到滿意。
The valuation has now gone up. So taking a measured pace on this was the right thing to do. We think it will continue to be the right thing to do. We will comfortably stay out there with at least five quarters of cash on hand relative to our forward spend. And as you get a label or close to a label, that spend will accelerate.
估值現在已經上升了。因此,以審慎的步調來推進是正確的做法。我們認為這將持續是正確的做法。相較於我們未來的支出,我們會很從容地維持至少五個季度的現金在手。而當你取得標籤或接近取得標籤時,那個支出將會加速。
I will say we already have calls from some of the best of sales and the best of marketing say, as and if you get a label, don't lose my number, and here it is for the first time. That's the easiest area to add to and to complement what you have because you're getting calls from people that are competing with you now that well know how you stand. So that would be very difficult to go out and find a batch of engineers that could match or beat what we do. That's nigh near impossible.
我想說的是,我們已經接到一些頂尖銷售與頂尖行銷人才的來電,他們說:如果你們取得標籤,別把我的號碼弄丟了——這是我第一次把號碼給你。那是最容易補強、也最能與你現有能力互補的領域,因為你會接到目前正在與你競爭、而且很清楚你們實力定位的人的來電。所以,要出去找到一批能夠匹敵或超越我們所做事情的工程師,將會非常困難。那幾乎是不可能的。
There's other administrative duties, regulatory, et cetera, that are difficult to come by. So we will be prepared for that. And whatever that case may be, we do recognize this is a business that has entrenched sales and marketing, but we do note that Boston Scientific from out of nowhere took market share like they were the Goliath, and until it was viewed as a commodity, I mean, they had like a $40 billion market cap jump when it looked like a monopoly. So valuation will not be a problem, if you look at that, and attracting the right people will not be a problem.
還有其他行政職能、法規等方面的工作,也很難找到合適的人才。所以我們會為此做好準備。不管情況如何,我們確實認知到這是一個銷售與行銷根基深厚的產業,但我們也注意到,波士頓科學(Boston Scientific)幾乎是從無到有地搶下市占,彷彿他們才是巨人;而且在它被視為商品化之前,我是說,當看起來像壟斷時,他們的市值曾跳升了大約400億美元。所以如果你看那個案例,估值不會是問題,吸引到合適的人才也不會是問題。
Time is on our side. We look for the continuation of the trial and the very popular trial status will in a sense provide some early benchmark. You get physicians that are doing seven a day, that's like 35 a week. There will be a classic number of EPs that go after this. And we have dealt with all the KOLs, so, to really get to the number, you can check in with them as to what they see, how competitive this will be. But we're pretty optimistic and we're very aware.
時間站在我們這邊。我們期待試驗持續推進,而非常受歡迎的試驗狀態在某種意義上會提供一些早期基準。你會看到有醫師一天做七例,那等於一週35例。會有一個典型數量的電生理醫師(EP)投入追逐這個機會。而我們已經與所有關鍵意見領袖(KOL)打過交道,所以要真正掌握那個數字,你可以跟他們確認他們看到的情況、以及這會有多競爭。但我們相當樂觀,也非常清楚其中的狀況。
In my former Pharmacyclics company, remember, we've not been in the drug business priorly, and my team, other people that are on board here, we did $1 billion of revenue in the second year from out of nowhere. So we're not unfamiliar with what it takes to do that. I hope that helps to respond to the question and our preparedness for it.
在我之前的Pharmacyclics公司,請記得,我們先前並不在藥物業務領域,而我的團隊以及目前在這裡的其他成員,我們在第二年就從無到有做到了10億美元的營收。所以我們並不陌生於要做到那件事需要什麼。希望這能幫助回答這個問題,以及我們對此的準備程度。
Operator
Operator
Suraj Kalia, Oppenheimer.
Suraj Kalia,Oppenheimer。
Suraj Kalia - Analyst
Suraj Kalia - Analyst
Congrats on all the progress. So Paul, Bob, two questions. The first is a multi-part question, and just trying to get my arms around this. Paul, the fourth AAD added, I presume it's a calcium channel blocker. And maybe you could help us understand the average age of the patients now, is it going to end up being similar to the EFS? And maybe if you could just kind of help us on the math of 19 additional patients.
恭喜你們取得所有進展。所以Paul、Bob,兩個問題。第一個是多段式問題,我只是想把整體脈絡弄清楚。Paul,新增的第四種AAD,我猜應該是鈣離子通道阻斷劑。也許你可以幫我們理解一下目前病人的平均年齡,最後會不會跟EFS相近?另外,如果你也能幫我們算一下新增19位病人的邏輯就更好了。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Sure. So yes. So let's just level set for everybody. There are four classes of AADs. Two of which are calcium channel blockers, one sodium and then one beta blocker.
當然。所以,是的。我們先幫大家把基準釐清一下。AAD一共有四大類。其中兩類是鈣離子通道阻斷劑,一類是鈉離子通道阻斷劑,另外一類是β阻斷劑。
And the history of the field has generally driven patients to be non-responders at least in the Class 1 and Class 3. Current practice, though, if you think about what's going on in the marketplace today is that patients are in higher demand for earlier ablation. And that earlier ablation implies, yes, that patient still needs to be a non-responder to an AAD, but they don't want to go through the escalation of more severe drugs with greater toxicity and adverse effect profiles. So in order to keep the protocol contemporary with current clinical practice, we felt it was important to add the other two AAD classes so that they could fail any one of the classes.
而這個領域過去的歷史通常會讓病人至少在第1類與第3類上成為無反應者。不過,若你看看當今市場上的現況,現在的臨床實務是病人對更早期的消融治療需求更高。而更早期的消融意味著,是的,病人仍需要對某一種AAD無反應,但他們不想經歷逐步升級到更嚴重、毒性更高且不良反應特徵更明顯的藥物。因此,為了讓試驗方案符合當前臨床實務的趨勢,我們認為有必要把另外兩類AAD也納入,讓病人可以在任何一類上治療失敗即可。
Now, first question on patient age. I don't believe this will alter patient age. What this will potentially do, and the way we thought about the stats, the change in the enrollment number was to basically accept a question from FDA regarding the possibility that if you skewed more patients to being non-responders to a lower efficacy drug, it's possible that their AF burden could be slightly lower. So that leads to a potential question about performance goals, statistical rigor, and in order to bring equilibrium to all of those moving parts, we added patients.
接著第一個問題是病人年齡。我不認為這會改變病人年齡。這可能會帶來的影響,以及我們在統計上如何思考,是為了回應FDA的一個疑問:如果你讓更多病人成為對較低療效藥物的無反應者,那麼他們的心房顫動(AF)負荷可能會略低一些。因此就可能引出關於績效目標、統計嚴謹性等問題;為了讓這些變動因素達到平衡,我們增加了受試者人數。
I think the important part of our thought process there was that there's very little price for us to pay by adding 19 patients because our enrollment velocity is so high, that in order to keep all the stats balanced with the slight theoretical change in, call it, background risk of the phenotype of the enrollee, we'll add a few patients and it won't cost us anything because the time to enrollment would be essentially the same. So that's how we thought about it.
我認為我們思考過程中很重要的一點是:增加19位病人對我們而言幾乎沒有代價,因為我們的收案速度非常快;為了讓所有統計在這個輕微的理論性變化下——可以說是受試者表型的背景風險——仍保持平衡,我們就多加一些病人,而這不會讓我們付出任何成本,因為收案所需時間基本上會是一樣的。這就是我們的思考方式。
I don't believe it will change the age. And when you consider that we're not implementing this change until midway through the study. You then have the first half already having gone through the Class 1 and Class 3 non-response. The second half potentially being a mix of one through four, the larger patient population is going to be quite comparable. And we just bolstered our statistical assurance, if you will, by adding those 19 patients.
我不認為這會改變年齡。而且考量到我們直到研究進行到一半才會實施這項變更。那麼前半段的病人已經走過第1類與第3類無反應的條件。後半段可能會是第1到第4類的混合,因此整體更大的病人族群將會相當可比。而我們透過增加那19位病人,強化了我們的統計把握度(statistical assurance)。
Suraj Kalia - Analyst
Suraj Kalia - Analyst
Perfect. Paul, one quick question, and I'll hop back in queue. The rest of the patients to be enrolled in Nano-Pulse. Maybe I missed your commentary. I know everything has been done on EnSite so far.
很好。Paul,我再問一個快問,然後我就回到排隊序列。Nano-Pulse剩下要收案的病人。也許我漏聽了你的說明。我知道到目前為止全部都是在EnSite上完成的。
Should we glean from that the rest of the patients also will be on EnSite just for statistical purity here, and maybe if you could also share -- give us an idea of the 80-plus patients enrolled, what percent would be on the AADs and what are now on four AADs?
我們是否可以從中推論,剩下的病人也都會使用EnSite,以確保統計上的純度?另外你是否也能分享一下——在已收案的80多位病人中,大概有多少比例是在使用AAD?以及現在在四類AAD範圍內的又是多少?
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thank you, Suraj. You may have missed it. I did make the comment that all the patients so far have been enrolled using our system mapped with EnSite. We are not going to comment on any expected change in that. So I think staying the course, the safest assumption should be that the remaining patients also will be enrolled on EnSite. That would not, by the way, change anything in the statistics.
謝謝你,Suraj。你可能漏聽了。我確實有提到,到目前為止所有病人都是使用我們的系統並以EnSite進行建圖而收案的。我們不會評論這方面是否會有任何預期的變更。所以我認為,維持既定方向,最保守且安全的假設應該是:其餘病人也會在EnSite上收案。順帶一提,這不會改變任何統計結果。
To your question, our IDE actually allows us to use any available commercial mapping system. So there is no anticipated outcome difference. It really comes down to the -- really the quality of the feel and the representation of our catheter on those systems in the lab. So that's point number one.
針對您的問題,我們的 IDE 其實允許我們使用任何可用的商用電解剖標測系統。因此,預期不會有結果上的差異。真正關鍵在於——也就是在實驗室裡,我們的導管在這些系統上的手感品質與呈現效果。這是第一點。
And then point number two, we are not going to comment on the specific AAD, I'd say, regimen of the first half of the population, the second half of the population. I would say physicians generally feel they can enroll with greater ease by using a more liberal definition of AAD class non-responder. But we don't expect it to translate through to any difference in the first half and second half of the study population.
第二點,我們不會評論特定的 AAD(抗心律不整藥物)——我會說——在受試者族群前半段、後半段的用藥方案。我會說,醫師普遍覺得,採用對 AAD 類別無反應者較寬鬆的定義,會更容易納入受試者。但我們不預期這會轉化為研究族群前半段與後半段之間的任何差異。
Given that, again, our principal goal here is to really make it easier for the clinical community to address patients who are now in the real world moving faster from diagnosis to ablation than they would have prior to the availability of PFA in the marketplace.
基於此,再次強調,我們在這裡的主要目標,是讓臨床社群更容易處理那些在真實世界中、相較於 PFA 在市場上可用之前,從診斷到消融進程更快的病人。
Operator
Operator
Josh Jennings, TD Cowen.
Josh Jennings,TD Cowen。
Joshua Jennings - Analyst
Joshua Jennings - Analyst
I wanted to just ask about the procedural efficiency you're seeing in the IDE study. The protocol, I think, is just general anesthesia for each patient. So it sounds like from your download, and I would imagine that physicians are having aha moments as they're doing six, seven cases in one day. And have any of them, kind of, forecast how many procedures using nPulse AFib ablation procedures they could do in an ASC, when, like, conscious sedation is used? I imagine some may be thinking about double-digit days, but I wanted to ask that, and I've got a follow-up.
我想請教一下你們在 IDE 研究中看到的手術效率。我記得方案規定每位病人都採全身麻醉。所以聽起來,從你們分享的情況來看,我也想像醫師在一天做六、七台時會有「啊哈」時刻。那有沒有任何人預估過,如果在 ASC(門診手術中心)採用清醒鎮靜時,使用 nPulse AFib 消融手術一天可以做多少台?我猜有些人可能在想雙位數的日量,但我想問一下,另外我還有個追問。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thanks, Josh. You're right. The protocol does call for general anesthesia. So one of the, I think, key observations that we have is that the relative time efficiency that we can deliver is technically impaired, right, by the protocol and by the way we're treating these patients. And that in the real world, that you would have higher throughput when a lab is thinking purely commercial cases, morning, midday and afternoon, multiple rooms, and patient throughput and efficiency.
謝謝你,Josh。你說得對。方案確實要求全身麻醉。所以我們的一個——我想——關鍵觀察是,我們能提供的相對時間效率在技術上會受到影響,對吧?因為方案以及我們治療這些病人的方式。而在真實世界中,當導管室純粹在做商業病例、上午中午下午、同時多間手術室運作時,病人流轉與效率會更高。
When you enter a patient in a protocol, you're more focused on great results, capturing data, and if it takes 10, 20 more minutes, you don't really think about that on a given day. Now, one of the dynamics we've emphasized, and this is key to Bob's point, and I'm sure he'd be interested in commenting as well, this is about the translation of efficiency through to hospital economics. And we are actually asking our sites to try, if it's within their management approach, to stack some cases.
當你把病人納入試驗方案時,你更專注於取得很好的結果、蒐集數據;如果多花 10、20 分鐘,在某一天其實不太會去在意。現在,我們一直強調的一個動態——這也是 Bob 的重點——而且我相信他也會有興趣補充評論——是效率如何轉化為醫院經濟效益。我們其實也在要求各研究中心,如果符合他們的管理方式,嘗試把一些病例「堆疊」安排。
Let's try to do back-to-back cases. That does a couple of things. It's more efficient for the completion of the IDE, but it really forces them to experience what a day in the life would be like in the real world when this technology is available and when you can do three and four or five or seven cases back-to-back and experience what that is like, you get both the acute benefit in that case, hey, my ablation time was only six or eight minutes in total.
我們來試著連續做、背靠背做。這會帶來幾件事。這對 IDE 的完成更有效率,但也會迫使他們去體驗:當這項技術可用、在真實世界的一天會是什麼樣子;當你可以連續做三台、四台、五台甚至七台,親身感受那是什麼樣子,你會同時得到急性期的好處——例如,嘿,我的總消融時間只有六到八分鐘。
But then you also get the sense when that patient has turned over to the next, to the next, to the next, and now you've done four or five cases and it's only 1:00, this is what is creating such a positive enthusiasm and expectation for this technology going forward. You could then take that, yes, into the ASC. And we have done patients, of course, not in an ASC in the US, but we have done patients with sedation protocols in Europe. And so we believe that's going to be quite feasible.
但你也會感受到:當這位病人交接到下一位、再下一位、再下一位,而你已經做了四、五台,時間卻才下午 1 點,這正是為什麼大家對這項技術未來充滿非常正面的熱情與期待。然後你也可以把這套模式帶到 ASC。當然,我們在美國沒有在 ASC 做過病人,但我們在歐洲確實用鎮靜方案做過病人。因此我們相信這會相當可行。
And of course, that is an unlock for ASC conversion in the future. So we do think multiple cases per day will be feasible. We do think labs will be thinking about how to make the downtime, right? It's less about now the time that Pulse consumes. It's about the non-ablative time in the case, and then it's about the movement of patients in and out of the lab and the turnover of that lab because the physician is not strained by these cases.
當然,這也將在未來解鎖把病例轉到 ASC 的可能性。所以我們確實認為一天做多台是可行的。我們也認為導管室會開始思考如何處理「停機時間」,對吧?現在重點不再是 Pulse 本身耗時多少。而是病例中非消融時間,還有病人進出導管室的動線與導管室的周轉,因為醫師不會被這些病例耗損。
And as a result, the physician can do multiple cases, and then it becomes more about, to use the analogy, the pit crew and the ability to turn over the room. And labs will be thinking about that because they know if they can do that low-value time more efficiently, they can bring higher throughput and do more cases, and that will translate directly to the ASC. And Bob, do you want to make any further comments about hospital economics?
因此醫師可以做多台,接著就更像——用個比喻——維修站的「進站團隊」以及房間周轉的能力。導管室會思考這件事,因為他們知道如果能更有效率地縮短這些低價值時間,就能提高吞吐量、做更多台,而這會直接轉化到 ASC。Bob,你要不要再補充一些關於醫院經濟效益的看法?
Robert Duggan - Independent Co-Chairman of the Board
Robert Duggan - Independent Co-Chairman of the Board
Yes, just the number of procedures that I've been fortunate enough to be in that the doctors walk away at, and I've seen two of them at the seven level just fresh, ready to do more. We're going to come back the next morning. This is huge for not only the doctor and their sanity, but for the hospital and its return. You really look at seven cases exceeds the revenue, the cost of capital of the generator. So the economics are superb here.
是的,就我有幸參與的手術數量來看,醫師做完後走出來的狀態——我看過其中兩次是做到七台的水準——仍然精神飽滿、準備好再做更多。我們隔天早上還會再回來。這不僅對醫師及其身心狀態很重要,對醫院及其回報也很重要。你真的去看,七台病例所帶來的收入,已經超過發生器的資本成本。所以這裡的經濟性非常出色。
And we want a label, we want this done efficiently and we want smiles on everybody's faces, including the patient. Patients, by and large, if they have something less than full anesthesia, would rather do it if they knew for sure the outcome was the match and nothing less than full anesthesia. So I believe that is chapter two. Some have been done. They look good, but we won't be doing that in the trial.
而我們希望有一個標示(label),希望能高效率地完成,也希望每個人都面帶笑容,包括病人。大多數病人,如果能用低於全身麻醉的方式,會更願意接受——前提是他們確定療效結果能與全身麻醉相匹配,而不是更差。所以我相信那是第二章。有些已經做過了。看起來不錯,但我們不會在這項試驗中進行。
Let's get through the trial, get the approval, and that's an uplift to be looked at as we get through regulatory approval and commercialization. But it's very practical and very doable. And yes, so I think, Josh, you're looking at it the right way. And it's really another differentiator. I think it's very, very difficult to pull that off with any pulse other than a pulse that stimulates regulated cell death, which other pulses have a very difficult time if they can do it at all; we do it consistently.
先把試驗做完、拿到核准,然後在我們完成法規核准與商業化的過程中,這會是一個可以再評估的提升項目。但它非常務實、也非常可行。是的,所以我想,Josh,你的看法是對的。而且這確實是另一個差異化因素。我認為,除了能誘發受調控的細胞死亡的脈衝之外,要做到這點非常、非常困難;其他脈衝要做到非常困難,甚至可能根本做不到;而我們能夠一致地做到。
Remember, the nsPulse is a 1,000-fold faster than the micropulse. You penetrate into the cell at a pace that the cell does not interbulate the inner cell working. So we're -- it's a powerful technology. We'll take it one step at a time, but it looks really, really good. Highly, highly differentiated.
記住,nsPulse 的速度比微脈衝快 1,000 倍。你以一種細胞來不及進行內部調節運作的速度穿透進入細胞。所以我們——這是一項強大的技術。我們會一步一步來,但看起來真的、真的很好。差異化非常、非常明顯。
All in the direction of better for the physician, better for the OR owner, and better for the patient.
一切都朝著對醫師更好、對手術室(OR)所有者更好、以及對病患更好的方向前進。
Joshua Jennings - Analyst
Joshua Jennings - Analyst
Thanks for sharing those answers and just one follow-up on them. I mean, just looking at the first in-human data and AFib symposium at the HRS, nPulse seems to have the potential to deliver a differentiated efficacy profile, maybe even a record kind of freedom from atrial arrhythmia rate in the IDE study, but in a scenario where, you know, it comes closer or even in line to the efficacy rates of competing AFib ablation technology or pulsed field ablation technologies and what you're talking about in terms of the economic value proposition that's coming into play.
感謝分享這些回答,我再追問一點。我的意思是,從首次人體資料以及在 HRS 的房顫(AFib)研討會來看,nPulse 似乎有潛力呈現差異化的療效表現,甚至可能在 IDE 研究中創下某種「無房性心律不整」比率的紀錄;但若在某種情境下,你知道的,它的療效率更接近、甚至與競爭的房顫消融技術或脈衝場消融(PFA)技術的療效率一致,而你所談到的經濟價值主張也開始發揮作用。
I mean, that would potentially still be a home run for Pulse Biosciences and the platform just in terms of the adoption trajectory. Have you had discussions like that with any investigators or any KOLs in terms of where they're thinking about the efficacy bar needs to be? And clearly, I'm not suggesting that it will be lower. Very strong preliminary signals in play already.
我的意思是,就採用軌跡而言,這對 Pulse Biosciences 和這個平台仍可能會是一記全壘打。你是否曾與任何研究者或任何 KOL 討論過這類問題,關於他們認為療效門檻需要達到什麼程度?而且很明顯,我並不是在暗示門檻會更低。目前已經出現非常強的初步訊號。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thanks, Josh. I think --
謝謝你,Josh。我想--
Robert Duggan - Independent Co-Chairman of the Board
Robert Duggan - Independent Co-Chairman of the Board
Paul, you're the best one to answer that. But just on the top of this, Josh, an nsPulse delivered as we deliver it kills the cells. A dead cell, unless they are cousin of Lazarus, does not come back. A stunned cell, which can be otherwise the appearance of a dead cell, can come back. So I look at it that the reason that you report and you're on the OR table is AF tachycardia, bradycardia.
Paul,你最適合回答這個問題。不過先就這點來說,Josh,我們所施作的 nsPulse(以我們的方式施作)會殺死細胞。死細胞,除非它們是拉撒路的遠親,否則不會復活。而「受創但未死」的細胞,外觀上可能看起來像死細胞,卻可能會恢復。所以我看待這件事的方式是:你之所以被通報、你之所以躺在手術室(OR)檯上,是因為房性心動過速、心動過緩。
There are many ways to accrue brady and tachycardia. But the way that you came into that OR, that means in that mechanism, you're not coming back when you're treated with nsPFA. Now, you may come up with -- you may marry someone else or lose money in the stock market or do whatever you do and have your heart go wild on it, and you could be back. We can't prevent other forms. But the reason that you reported in, that one's handled -- irreversibly handled.
造成心動過緩與心動過速的方式有很多。但你之所以會進到那間手術室,代表在那個機轉下,當你接受 nsPFA 治療後,你不會再因為同一個原因回來。當然,你可能會——你可能改跟別人結婚、或在股市賠錢、或做任何你會做的事,讓你的心臟因此失控,然後你可能又會回來。我們無法預防其他形式。但你當初來就醫的那個原因,已經被處理——而且是不可逆地處理。
Dead cells don't come back, and we maintain that any other form of ablation can kill and can stun and have the appearance of dead cells, but somehow they seem to have recurrences. We're not going to be in that class. So that puts us in a good position, but it doesn't mean that you will never have another. You may have tachycardia today and two years later have bradycardia. That's just the human physiology.
死細胞不會回來,而我們認為其他任何形式的消融可能既能殺死細胞、也可能只是讓細胞受創,呈現出死細胞的外觀,但不知為何它們似乎仍會復發。我們不會屬於那一類。所以這讓我們處於有利位置,但這不代表你永遠不會再發生。你今天可能是心動過速,兩年後可能變成心動過緩。這就是人體生理。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
And yes, I agree with Bob 100%. I think the way I would add further to that, Josh, is that let's assume that our data are exactly replicated from Europe and that we post a 90% Kaplan-Meier outcome across all atrial arrhythmias. That's going to be questioned, right?
是的,我 100% 同意 Bob。Josh,我想我可以再補充的是:假設我們的數據與歐洲的結果完全重現,並且在所有房性心律不整上呈現 90% 的 Kaplan-Meier 結果。那會被質疑,對吧?
Competition in the marketplace will say, well, that was a single study, it's not head-to-head. And they will say, that that was still a relatively small data set, we've done 100,000 cases. So I think the market will accept that if we post that feasibility data, and by the way the feasibility cohort will be double, right, in terms of one-year follow-up by then. Then we have the IDE data followed a year. That will be compelling.
市場上的競爭者會說,嗯,那只是單一研究,並非頭對頭比較。他們也會說,那仍然是一個相對小的資料集,而我們已經做了 100,000 例。所以我認為市場會接受我們若公布那個可行性數據;順帶一提,到那時可行性隊列在一年追蹤方面將會加倍,對吧。接著我們還會有 IDE 數據並追蹤一年。那將會很有說服力。
You put those two data sets together. It's going to be, I think, very impressive. But I yield to the scientific community to say, until we've seen 10,000 patients, until we've seen this or that, we're not entirely convinced. But at that point they say, you know, actually, the acute performance is so good, and I'm predisposed to believe in better outcomes, even if it's not definitive head-to-head across a 5,000-patient study.
把這兩組數據放在一起。我認為會非常令人印象深刻。但我也尊重科學界的看法:在我們看到 10,000 名病患、看到這個或那個之前,他們不會完全信服。不過到那個時候,他們會說,你知道的,急性期表現真的非常好,而我也傾向相信會有更好的結果,即使它不是在一項 5,000 名病患研究中的決定性頭對頭比較。
The market is going to switch. The market has switched heretofore, based on acute performance, where there's been zero differentiation across outcomes. And so to add another leap in acute performance and complement that with a likely superior outcome still to be added to with more and more studies and more real-world evidence, I think that physicians are looking at that saying, you know what, I don't need any more than that to switch.
市場會轉向。過去市場之所以轉向,是基於急性期表現,即便在結局上完全沒有差異化。因此,若急性期表現再往前躍進一步,並以可能更優的結局作為補強——而這些結局仍將透過越來越多研究與更多真實世界證據持續累積——我認為醫師會看著這些說,你知道嗎,我不需要更多就足以轉換。
Operator
Operator
And with no further questions in queue, I'll now return the call back to Paul for closing remarks.
由於佇列中沒有更多問題,我現在把電話交回給 Paul 作結語。
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Paul LaViolette - Co-Chairman of the Board, Chief Executive Officer and President
Thank you, operator. And thank you for those questions. Thank you all for your interest in Pulse Biosciences. We look forward to providing further updates on our progress, and I just want to wish everyone a good day, and thank you all for joining.
謝謝你,接線員。也謝謝這些問題。感謝各位對 Pulse Biosciences 的關注。我們期待就我們的進展提供更多更新;我也想祝大家有美好的一天,並感謝各位參與。
Operator
Operator
Thank you again for joining us today. This does conclude today's conference call. You may now disconnect.
再次感謝各位今天加入我們。今天的電話會議到此結束。您現在可以掛線。